Related content

Second-Generation Antipsychotic Medications and Risk of Pneumonia in Schizophrenia

By Kuo Chian-Jue   Yang Shu-Yu   Liao Ya-Tang   Chen Wei J.   Lee Wen-Chung   Shau Wen-Yi   Chang Yao-Tung   Tsai Shang-Ying   Chen Chiao-Chicy  

Schizophrenia Bulletin, Vol. 39, Iss. 3, 2013-05 ,pp. : 648-657

Oxford University Press

Access to resources Recommend Favorite

Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study

By Grohmann R.   Engel R.   Möller H.-J.   Rüther E.   Velden J.   Stübner S.  

European Archives of Psychiatry and Clinical Neuroscience, Vol. 264, Iss. 2, 2014-03 ,pp. : 131-141

Springer Publishing Company

Access to resources Recommend Favorite

Cardiovascular risk in patients admitted for psychosis compared with findings from a population-based study

By Johnsen Erik   Gjestad Rolf   Kroken Rune A.   Mellesdal Liv   Løøberg Else-Marie   Jøørgensen Hugo A.  

Nordic Journal of Psychiatry, Vol. 65, Iss. 3, 2011-06 ,pp. : 192-202

Informa Healthcare

Access to resources Recommend Favorite

Second-Generation Antipsychotic Agents: A Review of Safety Profiles

By  

Current Psychiatry Reviews, Vol. 8, Iss. 1, 2012-02 ,pp. : 49-68

Bentham Science Publishers

Access to resources Recommend Favorite

Metabolic Risk with Second-Generation Antipsychotic Treatment: A Double-Blind Randomized 8-Week Trial of Risperidone and Olanzapine

By Kelly Deanna  

Annals of Clinical Psychiatry (after Jan 1, 2004), Vol. 20, Iss. 2, 2008-05 ,pp. : 71-78

Informa Healthcare

Access to resources Recommend Favorite